Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002478:Cells, Cultured; D003429:Cross Reactions; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use*; D004351:Drug Resistance; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D003561:Cytarabine; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D015122:Mercaptopurine; D008727:Methotrexate; D003630:Daunorubicin